Literature DB >> 24719434

Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States.

Paschalis Vergidis1, Raymund R Razonable1, L Joseph Wheat2, Lynn Estes1, Angela M Caliendo3, Lindsey R Baden4, John R Wingard5, John Baddley6, Maha Assi7, Steven Norris8, Pranatharthi Chandrasekar9, Ryan Shields10, Hong Nguyen10, Alison Freifeld11, Richard Kohler12, Martin Kleiman13, Thomas J Walsh14, Chadi A Hage15.   

Abstract

Piperacillin-tazobactam (PTZ) is known to cause false-positive results in the Platelia Aspergillus enzyme-linked immunoassay (EIA), due to contamination with galactomannan (GM). We tested 32 lots of PTZ and 27 serum specimens from patients receiving PTZ. GM was not detected in the lots of PTZ; one serum specimen (3.7%) was positive. PTZ formulations commonly used in the United States today appear to be a rare cause for false-positive GM results.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24719434      PMCID： PMC4042793          DOI： 10.1128/JCM.00285-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  11 in total

1.  False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam.

Authors:  Annie Sulahian; Sophie Touratier; Patricia Ribaud
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

2.  Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies.

Authors:  Olivier Adam; Anne Aupérin; Fanny Wilquin; Jean-Henri Bourhis; Bertrand Gachot; Elisabeth Chachaty
Journal:  Clin Infect Dis       Date:  2004-02-27       Impact factor: 9.079

Review 3.  Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders.

Authors:  Johan Maertens; Koen Theunissen; Tom Lodewyck; Katrien Lagrou; Johan Van Eldere
Journal:  Mycoses       Date:  2007       Impact factor: 4.377

4.  The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-D-glucan in patients without risk factors for invasive fungal infections.

Authors:  G Metan; C Ağkuş; H Buldu; A N Koç
Journal:  Infection       Date:  2010-03-17       Impact factor: 3.553

5.  False positive galactomannan Platelia due to piperacillin-tazobactam.

Authors:  M P Gerlinger; P Rousselot; S Rigaudeau; C Billon; S Touratier; S Castaigne; O Eloy
Journal:  Med Mal Infect       Date:  2011-12-05       Impact factor: 2.152

6.  Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders.

Authors:  Alban Aubry; Raphael Porcher; Julie Bottero; Sophie Touratier; Thierry Leblanc; Benoît Brethon; Philippe Rousselot; Emmanuel Raffoux; Jean Menotti; Francis Derouin; Patricia Ribaud; Annie Sulahian
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

7.  Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance.

Authors:  Kieren A Marr; S Arunmozhi Balajee; Lisa McLaughlin; Marc Tabouret; Christopher Bentsen; Thomas J Walsh
Journal:  J Infect Dis       Date:  2004-07-01       Impact factor: 5.226

8.  Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction.

Authors:  Thomas J Walsh; Shmuel Shoham; Ruta Petraitiene; Tin Sein; Robert Schaufele; Amy Kelaher; Heidi Murray; Christine Mya-San; John Bacher; Vidmantas Petraitis
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

9.  Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications.

Authors:  Marisa H Miceli; Monica L Grazziutti; Gail Woods; Weizhi Zhao; Mehmet H Kocoglu; Bart Barlogie; Elias Anaissie
Journal:  Clin Infect Dis       Date:  2008-05-01       Impact factor: 9.079

10.  False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam.

Authors:  Claudio Viscoli; Marco Machetti; Paola Cappellano; Barbara Bucci; Paolo Bruzzi; Maria Teresa Van Lint; Andrea Bacigalupo
Journal:  Clin Infect Dis       Date:  2004-02-27       Impact factor: 9.079
View more
  18 in total

Review 1.  Antifungal stewardship considerations for adults and pediatrics.

Authors:  Rana F Hamdy; Theoklis E Zaoutis; Susan K Seo
Journal:  Virulence       Date:  2016-09-02       Impact factor: 5.882

Review 2.  Pneumonia in the neutropenic cancer patient.

Authors:  Scott E Evans; David E Ost
Journal:  Curr Opin Pulm Med       Date:  2015-05       Impact factor: 3.155

3.  Prospective Biomarker Screening for Diagnosis of Invasive Aspergillosis in High-Risk Pediatric Patients.

Authors:  Juergen Loeffler; Julia Hafner; Carlo Mengoli; Clemens Wirth; Claus Peter Heussel; Claudia Löffler; P Lewis White; Andrew J Ullmann; Denise Michel; Verena Wiegering; Matthias Wölfl; Paul Gerhardt Schlegel; Hermann Einsele; Jan Springer; Matthias Eyrich
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

4.  Generic piperacillin/tazobactam is not associated with galactomannan false-positivity in adult patients with cancer: a case-control study.

Authors:  J-H Ko; K R Peck; W J Lee; J Y Lee; S Y Cho; Y E Ha; C-I Kang; D R Chung; C W Jung; E-S Kang; J-H Song
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-17       Impact factor: 3.267

Review 5.  Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children.

Authors:  Anna R Huppler; Brian T Fisher; Thomas Lehrnbecher; Thomas J Walsh; William J Steinbach
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

6.  The utility of contrast-enhanced hypodense sign for the diagnosis of pulmonary invasive mould disease in patients with haematological malignancies.

Authors:  Claudia Sassi; Marta Stanzani; Russell E Lewis; Giancarlo Facchini; Alberto Bazzocchi; Michele Cavo; Giuseppe Battista
Journal:  Br J Radiol       Date:  2018-01-10       Impact factor: 3.039

7.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

8.  Clinical features and cause analysis of false positive results of Aspergillus galactomannan assay in pulmonary cryptococcosis patients.

Authors:  Takahiro Takazono; Tomomi Saijo; Nobuyuki Ashizawa; Kazuhiro Oshima; Keitaro Nishimura; Masato Tashiro; Kazuko Yamamoto; Yoshifumi Imamura; Taiga Miyazaki; Katsunori Yanagihara; Hiroshi Mukae; Koichi Izumikawa; Donald C Sheppard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-01-25       Impact factor: 3.267

9.  Challenges with Utilizing the 1,3-Beta-d-Glucan and Galactomannan Assays To Diagnose Invasive Mold Infections in Immunocompromised Children.

Authors:  Alice J Hsu; Pranita D Tamma; Sean X Zhang
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

10.  American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients.

Authors:  Sanjeet S Dadwal; Tobias M Hohl; Cynthia E Fisher; Michael Boeckh; Genofeva Papanicolaou; Paul A Carpenter; Brian T Fisher; Monica A Slavin; D P Kontoyiannis
Journal:  Transplant Cell Ther       Date:  2021-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.